Most of what has been written about Zepbound in Canada was written before it was available here. That is why so much of it is wrong. It has been authorized by Health Canada since May 2025. It has been in Canadian pharmacies since that July. Here is what is accurate now.
Key takeaways
- Zepbound is a brand name for tirzepatide, a once-weekly injectable medication that activates two hormone receptors, GIP and GLP-1.
- Health Canada first authorized it in May 2025. It became available in Canadian pharmacies in July 2025.
- In June 2026, Health Canada authorized an additional use: moderate to severe obstructive sleep apnea in adults with obesity. It was the first medication authorized in Canada for that purpose.
- It is given as a once-weekly injection using a single-dose prefilled pen, starting at a low dose that increases gradually.
- Gastrointestinal side effects are the most common, and they cluster during the period when the dose is being increased.
- It is prescription-only. Eligibility is assessed on body mass index and related health conditions, and provincial plans generally do not cover this class for weight management.
What Zepbound is
Zepbound is one of two Canadian brand names for the active ingredient tirzepatide. Tirzepatide is a once-weekly injectable that activates the glucose-dependent insulinotropic polypeptide receptor, known as GIP, and the glucagon-like peptide-1 receptor, known as GLP-1. Both are gut hormone receptors involved in appetite, fullness, blood sugar regulation, and the rate at which the stomach empties.
Acting on both receptors rather than one makes it structurally different from the semaglutide products, which act on the GLP-1 receptor alone. Health Canada describes it as the first and only authorized product in this category here that activates both.
The other Canadian tirzepatide product is authorized for type 2 diabetes. Same molecule, same weekly schedule, different authorized use. Our guide to tirzepatide in Canada covers that distinction in more detail.
What Health Canada authorized it for
There are two authorized uses, and the second one is recent enough that most articles have not caught up.
Chronic weight management. Authorized in May 2025 for once-weekly use, alongside a reduced-calorie diet and more physical activity. It covers both weight loss and weight maintenance. Eligibility starts at a body mass index of 30, or 27 if you also have a weight-related health condition. Health Canada lists those conditions as high blood pressure, abnormal cholesterol, prediabetes, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease.
Obstructive sleep apnea. Authorized in June 2026 for moderate to severe sleep apnea in adults with obesity, meaning a body mass index of 30 or higher. Again alongside diet and physical activity changes. This was the first medication authorized in Canada for this use.
That second authorization matters beyond people with sleep apnea. It is the clearest signal yet that Health Canada is reviewing this class for specific health outcomes, and not for weight alone.
What the sleep apnea evidence showed
Obstructive sleep apnea is a condition in which breathing repeatedly stops during sleep, typically for 10 to 30 seconds at a time. Each pause lowers blood oxygen and briefly rouses the sleeper without fully waking them. Repeated through the night, it prevents restful sleep. It is closely linked with obesity.
In the trials supporting the Canadian authorization, adults with obesity and moderate to severe obstructive sleep apnea were assessed on how many breathing interruptions they had per hour of sleep.
| Group | Tirzepatide | Placebo |
|---|---|---|
| Adults not using PAP therapy | 25 fewer per hour | 5 fewer per hour |
| Adults using PAP therapy | 29 fewer per hour | 6 fewer per hour |
After one year, 42 percent of adults taking tirzepatide without PAP therapy had either remission or mild, non-symptomatic sleep apnea, compared with 16 percent on placebo.
One point Health Canada was explicit about, and it is worth repeating without softening: anyone using a CPAP machine should not stop using it without guidance from their doctor. The medication was studied alongside PAP therapy, not as a replacement for it.
How it is given
Zepbound is a subcutaneous injection given once a week, on the same day each week, using a single-dose prefilled pen. It can be injected into the abdomen, thigh, or upper arm.
Treatment starts low and increases in steps over several weeks. That schedule is not arbitrary. Gastrointestinal side effects cluster during dose increases. Stepping up slowly is what makes the medication tolerable for most people. Your prescriber sets the schedule and decides whether and when to move up.
New to weekly injectables? How weight loss injections work covers the mechanics. Your first 90 days on weight loss medication covers what the early months tend to feel like.
Side effects and safety
The most commonly reported side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. In clinical trials most were mild to moderate and occurred during dose escalation.
Reported risks for this class that are less common but more serious include pancreatitis and gallbladder problems. Tirzepatide carries a warning about thyroid C-cell tumours based on rodent studies. Whether that finding applies to humans has not been established. That is why a personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2, is part of the assessment.
A clinician needs to review your medical history and current medications first. That includes any history of pancreatitis, gallbladder disease, thyroid cancer, severe gastrointestinal conditions, or diabetic retinopathy. It also includes whether you are pregnant, breastfeeding, or planning a pregnancy. If you are experiencing symptoms that concern you, speak with a healthcare provider about whether treatment may be appropriate for you.
It is also worth knowing before you start that evidence from this class indicates weight tends to return after treatment stops. In a semaglutide trial extension, participants regained about two thirds of lost weight within a year of stopping, and cardiometabolic improvements largely reverted. Treatment for a chronic condition is generally framed as ongoing rather than a fixed course.
Zepbound in Canada: access and cost
Zepbound is prescription-only in Canada. There is no route to it that skips a clinical assessment, and products marketed without one have not been reviewed by Health Canada for safety, efficacy, or quality.
Coverage is the part that catches people out. Provincial public drug plans generally cover medications in this class for type 2 diabetes and generally do not cover them for weight management. Private plan coverage for weight management is inconsistent. Many Canadians pay out of pocket. Cost differs by dose and by pharmacy. Ask for the price of the exact dose you are prescribed, rather than trusting a figure from an article.
Frequently asked questions
Is Zepbound available in Canada?
Yes. Health Canada authorized it in May 2025 and it became available in Canadian pharmacies in July 2025. It is prescription-only and is given as a once-weekly injection.
What is Zepbound approved for in Canada?
Two uses. Chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition, alongside diet and physical activity changes. And moderate to severe obstructive sleep apnea in adults with obesity, authorized in June 2026.
How much does Zepbound cost in Canada?
Cost depends on the dose and the pharmacy. Provincial drug plans generally do not cover this class for weight management, and private coverage varies, so many people pay out of pocket. Ask for the price of your specific prescribed dose before starting.
What is the difference between Zepbound and the other tirzepatide product in Canada?
The active ingredient and the weekly dosing schedule are the same. What differs is the authorized use. Zepbound is authorized for chronic weight management and for obstructive sleep apnea with obesity. The other product is authorized for type 2 diabetes.
Can Zepbound replace a CPAP machine?
No. It was studied alongside PAP therapy rather than as a substitute for it, and Health Canada has stated that patients should not stop using their CPAP machine without their doctor’s guidance.
How long does it take to see results?
In the trials, weight reduction continued over 72 weeks rather than plateauing early, and the dose is increased gradually over the first several weeks. Individual response varies considerably, and some participants in these trials saw little change.
The bottom line
Zepbound has been authorized and available in Canada since 2025, and now carries two authorized uses: chronic weight management and obstructive sleep apnea in adults with obesity. It is a once-weekly tirzepatide injection. Gastrointestinal side effects are the main trade-off. Most provincial plans do not cover it for weight management. And the evidence points toward long-term rather than short-term use.
To find out whether it is appropriate for you, start an online assessment with MyRocky and speak with a licensed Canadian healthcare provider.
References
- Eli Lilly Canada. Health Canada approves ZEPBOUND as the first-ever obstructive sleep apnea medication in Canada for adults living with obesity. June 16, 2026. https://www.lilly.com/en-ca/news/press-releases/zepbound-osa-noc
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
Disclaimer: This article is intended for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any questions about a medical condition or treatment.
Editorial Standards: At Rocky Health, we’ve made it our mission to support men and women with trustworthy, easy-to-understand medical and health information online. Read more about our editorial standards here.
